HER2/neu at Dr. Essa Lab

HER2/neu at Dr. Essa Lab

The HER2/neu test is a highly specialized diagnostic pathology investigation used primarily in oncology to determine the status of the Human Epidermal Growth Factor Receptor 2 (HER2) protein and gene. At Dr. Essa Laboratory & Diagnostic Centre, this test is performed with extreme precision to guide therapeutic decisions for patients diagnosed with specific cancers, most notably invasive breast cancer and gastric or gastroesophageal junction adenocarcinoma. The HER2/neu gene, located on chromosome 17, encodes a transmembrane glycoprotein receptor with intrinsic tyrosine kinase activity. Under normal physiological conditions, this receptor regulates cell growth, survival, and differentiation. However, in approximately 15% to 20% of breast cancers, the HER2/neu gene is amplified, leading to an overexpression of the HER2 receptor protein on the cell surface. This overexpression drives uncontrolled cellular proliferation and tumor progression, resulting in an aggressive clinical phenotype.

Understanding your HER2/neu status is a critical step in modern oncology. The diagnostic value of this test lies in its ability to identify patients who will benefit from HER2-targeted therapies, such as trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), and other tyrosine kinase inhibitors. Historically, HER2-positive breast cancers carried a poor prognosis; however, the advent of targeted monoclonal antibodies has revolutionized treatment outcomes, making accurate HER2/neu testing a cornerstone of personalized cancer care. Dr. Essa Lab utilizes state-of-the-art immunohistochemistry (IHC) and, when necessary, fluorescence in situ hybridization (FISH) to analyze tissue specimens. This ensures that patients across Karachi and Pakistan receive highly reliable, clinically actionable results that directly influence their treatment pathways.

Clinical Procedure: What to Expect

Patient Preparation

The HER2/neu test is unique because it is not performed directly on the patient's body during their laboratory visit. Instead, it is carried out on a tissue specimen that has already been obtained through a previous surgical procedure, such as a core needle biopsy, lumpectomy, or surgical resection. Therefore, direct patient preparation is minimal, but administrative and logistical preparation is vital. Patients or their caregivers must obtain the formalin-fixed paraffin-embedded (FFPE) tissue block (often referred to as the “tumor block”) along with the corresponding histopathology slides and original pathology report from the facility where the biopsy or surgery was performed. It is essential to ensure that the tissue specimen has been fixed in 10% neutral buffered formalin within the recommended cold ischemia time (under one hour) and fixed for 6 to 72 hours, as per international ASCO/CAP guidelines, to preserve protein antigenicity and nucleic acid integrity. No fasting or special physical preparation is required from the patient to submit these samples at any Dr. Essa Lab collection center.

During the Procedure

Once the tissue block is submitted to the histopathology department at Dr. Essa Lab, our consultant pathologists and highly trained laboratory technologists initiate a rigorous analytical protocol. The paraffin block is mounted on a microtome, and ultra-thin sections (typically 4 to 5 micrometers thick) are cut and transferred onto specialized glass slides. For the primary screening, Immunohistochemistry (IHC) is performed. This process involves exposing the tissue sections to highly specific anti-HER2 primary antibodies, followed by a secondary detection system that produces a visible colored reaction (usually brown) where the HER2 protein is present on the cell membranes. The slides are counterstained, dehydrated, and mounted for microscopic evaluation. If the IHC result is equivocal (borderline), a molecular test called Fluorescence In Situ Hybridization (FISH) is performed on another section of the same block. FISH uses fluorescently labeled DNA probes to directly visualize and count the number of HER2 gene copies relative to the centromere of chromosome 17 (CEP17) under a specialized fluorescence microscope. This dual-testing paradigm ensures absolute diagnostic accuracy.

When is a HER2/neu Test Performed?

Invasive Breast Cancer Diagnosis

Oncologists request a HER2/neu test for every patient newly diagnosed with invasive breast cancer. This is a mandatory clinical standard because the HER2 status dictates whether the patient is a candidate for targeted therapy. Knowing the HER2 status at the time of diagnosis helps the clinical team formulate a comprehensive treatment plan, which may include neoadjuvant therapy (treatment before surgery to shrink the tumor) or adjuvant therapy (treatment after surgery to eliminate microscopic residual disease).

Gastric and Gastroesophageal Junction Adenocarcinoma

The test is also routinely performed for patients diagnosed with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Just as in breast cancer, a subset of gastric cancers overexpresses the HER2 protein. Identifying these patients allows oncologists to add trastuzumab to standard chemotherapy regimens, which has been clinically proven to improve overall survival and progression-free survival in this patient population.

Evaluation of Recurrent or Metastatic Cancer

If a patient experiences a cancer recurrence or if the disease metastasizes to distant organs (such as the liver, lungs, or bones), physicians will often request a repeat HER2/neu test on a biopsy of the metastatic lesion. This is because the HER2 status can occasionally change (discordance) between the primary tumor and the metastatic site. Confirming the current HER2 status is essential to ensure that the systemic therapy remains aligned with the tumor's biological profile.

Determining Eligibility for Targeted Therapy

The primary clinical indication for this test is to establish eligibility for highly effective, FDA-approved HER2-targeted drugs. Patients whose tumors are confirmed to be HER2-positive (IHC 3+ or FISH amplified) can receive targeted treatments that specifically bind to the HER2 receptor, blocking the downstream signaling pathways that promote cell division and survival, while sparing healthy cells from the generalized toxicity associated with traditional chemotherapy.

Risk Stratification and Prognostic Assessment

In addition to guiding therapy, HER2/neu status serves as an important prognostic indicator. HER2-positive tumors tend to grow and spread more rapidly than HER2-negative tumors. By identifying this aggressive biological subtype early, physicians can implement more intensive monitoring schedules and aggressive treatment protocols to mitigate the risk of recurrence and optimize long-term patient outcomes.

What Does a HER2/neu Test Detect?

The HER2/neu test evaluates specific cellular and genetic parameters to determine the presence and extent of HER2 alterations. The diagnostic findings include:

• IHC Score 0 (Negative): No membrane staining is observed, or faint, incomplete membrane staining is present in less than 10% of the tumor cells.
• IHC Score 1+ (Negative): Faint, barely perceptible, incomplete membrane staining is detected in more than 10% of the invasive tumor cells.
• IHC Score 2+ (Equivocal): Weak to moderate, complete membrane staining is observed in more than 10% of the tumor cells. This borderline result requires reflex testing via FISH to confirm gene amplification.
• IHC Score 3+ (Positive): Strong, intense, complete, and circumferential membrane staining is observed in more than 10% of the invasive cancer cells.
• HER2 Gene Amplification: Detected via FISH, indicating an abnormally high number of HER2 gene copies within the cell nuclei.
• HER2/CEP17 Ratio: A key FISH parameter comparing the number of HER2 gene signals to the number of chromosome 17 centromere signals. A ratio of 2.0 or greater indicates amplification.
• Average HER2 Copy Number: The average number of HER2 gene signals per cell; an average of 6.0 or more signals per cell is classified as positive/amplified.
• CEP17 Copy Number: Evaluates whether chromosome 17 polysomy (extra copies of the chromosome) is present, which can affect HER2 protein expression without true gene amplification.
• Heterogeneity of HER2 Expression: Identifies whether different areas of the tumor exhibit varying levels of HER2 expression, which is crucial for treatment planning.
• Gastric Cancer Specific Staining Patterns: Evaluates basolateral or lateral membrane staining, which is characteristic of HER2-positive gastric cancer cells, unlike the complete circumferential staining required in breast cancer.
• Invasive vs. In Situ Components: Ensures that HER2 evaluation is performed strictly on the invasive component of the tumor, as ductal carcinoma in situ (DCIS) can yield misleadingly high HER2 expression.
• Cell Membrane Integrity: Assesses the quality of the tissue preservation and staining to rule out artifacts that could cause false-positive results.
• Tumor Cell Percentage: Confirms that an adequate number of viable tumor cells (typically at least 100 cells) are present on the slide for reliable evaluation.
• Background Non-Neoplastic Tissue Staining: Verifies that normal breast or gastric cells show little to no staining, serving as an internal negative control.
• Control Slide Reactivity: Confirms that the laboratory's positive and negative control slides stained correctly, validating the run's technical accuracy.
• HER2-Low Status: Identifies tumors with IHC 1+ or IHC 2+ without FISH amplification, a newly recognized clinical category eligible for novel antibody-drug conjugates (ADCs).
• Atypical FISH Patterns: Detects rare genetic variations, such as co-amplification of the centromere or deletion of chromosome 17.
• Artifactual Staining: Identifies edge effects, crush artifacts, or necrotic areas that must be excluded from clinical interpretation.
• Nuclear vs. Cytoplasmic Staining: Distinguishes clinically irrelevant cytoplasmic staining from diagnostic membranous staining.
• Treatment-Induced Alterations: Detects changes in HER2 expression following neoadjuvant chemotherapy, helping to assess therapeutic response.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that waiting for cancer diagnostic results can be an anxious time for patients and their families. Our histopathology and molecular diagnostics departments prioritize HER2/neu cases to deliver highly accurate results as efficiently as possible. Typically, Immunohistochemistry (IHC) results are ready within 3 to 5 working days from the time the tissue block is received and verified. If the case requires reflex Fluorescence In Situ Hybridization (FISH) testing due to an equivocal IHC 2+ result, the additional molecular analysis may take an additional 5 to 7 working days, as FISH involves complex hybridization and specialized fluorescent microscopy protocols.

Dr. Essa Lab provides seamless access to diagnostic reports. Once finalized and signed off by our consultant pathologists, reports are immediately uploaded to our secure online database. Patients can access, view, and download their reports directly from the official Dr. Essa Lab website or through our dedicated mobile application using the unique patient ID and password printed on their receipt. Additionally, physical copies of the reports can be collected from any of our conveniently located diagnostic centers across Karachi and other major cities in Pakistan.

HER2/neu Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HER2 Protein Expression (IHC)	Score 0 or 1+ (No or minimal membrane staining)	Score 3+ (Strong, complete membrane staining in >10% of cells) or Score 2+ (Equivocal)
HER2/CEP17 Ratio (FISH)	Ratio less than 2.0	Ratio of 2.0 or greater (Indicates gene amplification)
Average HER2 Gene Copy Number	Less than 4.0 signals per cell	6.0 or more signals per cell (Amplified status)
Tumor Cell Membrane Staining Pattern	Unstained or incomplete, faint staining	Intense, circumferential (breast) or basolateral (gastric) membrane staining
Chromosome 17 Centromere (CEP17)	Normal diploid state (approx. 2 signals/cell)	Polysomy 17 (increased signals) or monosomy 17 (decreased signals)
Tumor Heterogeneity	Uniformly negative or normal cell expression	Clonal heterogeneity with mixed positive and negative tumor cell populations
Tissue Fixation Quality	Optimal preservation with clear cellular details	Poor fixation, leading to autolysis, weak antigenicity, or false-negative staining

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for HER2/neu?

• Experienced Healthcare Professionals: Our histopathology department is led by highly qualified consultant pathologists with extensive experience in oncological pathology and molecular diagnostics.
• Patient-Focused Care: We prioritize patient well-being, ensuring compassionate assistance throughout the sample submission and reporting process.
• Quality Diagnostic Services: Dr. Essa Lab adheres to strict internal and external quality control measures, aligning with international ASCO/CAP guidelines for cancer testing.
• Professional Reporting: We provide detailed, standardized pathology reports that offer clear, actionable insights for oncologists to plan targeted therapies.
• Modern Diagnostic Approach: Our laboratories are equipped with advanced automated staining platforms and high-resolution fluorescence microscopes to ensure diagnostic precision.
• Comfortable Environment: Our collection centers offer a clean, professional, and welcoming environment for patients submitting tissue specimens.
• Convenient Location: With an extensive network of branches across Karachi and Pakistan, patients can easily access our services close to home.
• Commitment to Accurate Diagnosis: Since 1987, Dr. Essa Lab has remained dedicated to delivering reliable diagnostic services, earning the trust of millions of patients and doctors.